HealthCholesterol drug setback casts doubt over multibillion-dollar race

Novartis’ failure raises the stakes for Amgen and Eli Lilly as they compete to lower Lp(a) levels and ultimately reduce heart attacks and strokes.

cholesterol drugsLp(a)NovartisAmgenEli Lilly

CCNBC★★☆☆☆2026-09-08 05:00Original